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Abstract
SIRPα, an ITIMs-containing signaling receptor, negatively regulates leukocyte responses through extracellular
interactions with CD47. However, the dynamics of SIRPα-CD47 interactions on the cell surface and the governing
mechanisms remain unclear. Here we report that while the purified SIRPα binds to CD47 and that SIRPα is
expressed on monocytes and monocytic THP-1 or U937, these SIRPα are ineffective to mediate cell binding to
immobilized CD47. However, cell binding to CD47 is significantly enhanced when monocytes transmigrating across
endothelia, or being differentiated into macrophages. Cell surface labeling reveals SIRPα to be diffused on naïve
monocytes but highly clustered on transmigrated monocytes and macrophages. Protein crosslink and equilibrium
centrifugation confirm that SIRPα in the latter cells forms oligomerized complexes resulting in increased avidity for
CD47 binding. Furthermore, formation of SIRPα complexes/clusters requires the plasma membrane ‘lipid rafts’ and
the activity of Src family kinase during macrophage differentiation. These results together suggest that ‘clustering’
SIRPα into plasma membrane microdomains is essential for activated monocytes and macrophages to effectively
interact with CD47 and initiate intracellular signaling.
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Introduction
Signal regulatory protein α (SIRPα) (also known as SHPS1,
CD172A, or P84) is a cell surface receptor-like signaling
protein predominantly expressed in myeloid leukocytes
including granulocytes, monocytes, macrophages and dendritic
cells [1,2]. The expression of SIRPα is also reported in other
specific types of cells such as neurons [3] and podocytes in the
kidney [4]. As a typical type-1 transmembrane protein, SIRPα
functions tightly correlate with its structure, which contains an
extracellular domain with a highly interactive IgV-like loop and
a cytoplasmic domain containing two immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) that are essential for signaling
[5]. SIRPα has been reported to be crucial for leukocyte
functions, including monocyte and neutrophil (PMN)
chemotactic transmigration [6,7], macrophage phagocytosis [8],
macrophage fusion [9], dendritic cell antigen presentation [10],
and other possible cellular functions such as neuronal axonal
growth and synapse formation [3] and kidney filtration [4]. The
regulation of all these cellular functions by SIRPα has been
attributed to its extracellular binding interactions with the ligand
CD47, another important cell surface protein broadly expressed
on most cells, and to the SIRPα ITIMs-mediated intracellular
signaling. It has been suggested that the extracellular binding
of SIRPα to CD47 triggers tyrosine phosphorylation in its
cytoplasmic ITIMs, resulting in the association of the SH2
domain-containing protein tyrosine phosphatase (SHP-1 or 2),
which consequently initiates negative signaling events leading
to the inhibition of cell function [11-16]. Studies of macrophage
phagocytosis indicate that ligation of macrophage SIRPα by
CD47 expressed on the encountered cells prohibits
macrophage phagocytosis, whereas failure of SIRPα
engagement by CD47, or deficiency of SIRPα ITIM-mediated
signaling, promotes macrophage engulfment of the cell
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[2,8,17-22]. It has also been suggested that increased CD47
expression on cancer cells serves as a crucial mechanism for
the evasion of immune clearance [23,24].
The evidence found for high affinity binding between the
extracellular domains of SIRPα and CD47 is convincing.
Experiments using recombinant SIRPα and CD47 extracellular
domains as well as transfected cells that overexpress the full-
length SIRPα or CD47 protein on the cell surface [7,25-27]
have demonstrated efficient binding between the two proteins.
Despite being expressed by different cell types, we previously
observed that CD47 purified from RBCs, leukocytes, spleen
cells, fibroblasts and epithelial cells all directly bound to SIRPα
[7]. Key amino acid residues in the SIRPα extracellular IgV-like
loop, which mediates binding to CD47, have also been
identified [26]. However, most of these experiments confirming
SIRPα-CD47 binding were performed in acellular or
transfection systems; cell functions implicating the involvement
of SIRPα-CD47 interactions were also observed often
indirectly, primarily through the usage of inhibitory antibodies
against SIRPα or CD47 or recombinant soluble proteins that
compete for binding. The interaction between SIRPα and CD47
on the surface of their native cells is not very clear. Moreover,
as cell interactions are often transient, the mechanisms that
regulate the dynamic binding and disengagement of SIRPα and
CD47 require further elucidation.
In this study, we report that peripheral monocytes, despite
the abundant cell surface expression of SIRPα, do not bind
CD47. We found that effective SIRPα-mediated cell binding to
CD47 occurs when monocytes are activated and/or
differentiated into macrophages. Our data indicate that
concomitant with monocyte activation/differentiation, SIRPα is
distributed into the cholesterol-rich lipid microdomains of the
plasma membrane, where it forms high density protein
complexes. With this “clustered” structure, SIRPα on the cell
surface mediates high avidity and effective binding interactions
with CD47.
Materials and Methods
Cells
Human peripheral polymorphonuclear leukocytes (PMN) and
peripheral blood mononuclear cells (PBMC) were isolated from
whole blood donated by healthy volunteers who provided
written informed consent according to the protocol approved by
the institutional review board of Georgia State University [7,28].
Monocyte leukemic cell lines THP-1 and U937 obtained from
American Tissue Culture Collection (ATCC) were cultured in
RPMI 1640 supplemented with 10% FBS. Additionally the
THP-1 medium contained 50µM β-mercaptoethanol. To induce
macrophage differentiation, THP-1 cells were cultured in the
presence of phorbol myristate acetate (PMA, 50 nM) for 3-4
days. Human microvascular endothelial cells (HMEC-1), kindly
provided by Dr. E.W. Ades (Centers for Disease Control and
Prevention, Atlanta) [29], were cultured in MCDB 131 medium
supplemented with 10 mM/L L-glutamine, 10 ng/ml mouse
epidermal growth factor (mEGF, BD Biosciences), 1 µg/ml
hydrocortisone (Sigma) and 10% FBS. Mouse NIH 3T3 cells,
which produce murine macrophage colony stimulating factor
(M-CSF), were kindly provided by Dr. David Weiss (Emory
University) and maintained in DMEM with 10% FBS. The
harvested medium containing M-CSF was used to induce the
differentiation of mouse bone marrow cells into macrophages
[30]. Mouse peritoneal macrophages (PEM) were obtained by
lavaging the peritoneal area with cold PBS followed by
centrifugation. CHO-SIRPα cells, which permanently express
the human SIRPα that was previously generated [26], and non-
transfected CHO cells were maintained in DMEM with 10%
FBS.
Antibodies, recombinant proteins and other reagents
Monoclonal antibodies (mAb) SE5A5 and SE7C2, against
SIRPα, and anti-CD47 mAb B6H12.2 were described
previously [7,26,28]. Polyclonal rabbit antibody against the
human SIRPα extracellular domain (anti-SIRPα.ex) was
generated by immunizing rabbits with a purified fusion protein
consisting GST and the entire extracellular domain of SIRPα
(SIRPα.ex-GST) [5]. After obtaining a highly reactive serum,
SIRPα-specific IgG was enriched by affinity purification using
protein A/G-conjugated Sepharose, and then passed through
SIRPβ.ex-GST-coated glutathione-Sepharose to eliminate the
cross-reactivity with the close SIRP family member SIRPβ [31].
A rabbit polyclonal antibody that recognizes the SIRPα
cytoplasmic terminus (anti-SIRPα.ct) was obtained from EMD
Millipore and was also generated in the lab; the antibody
detects SIRPα of both human and murine origins. The rat anti-
mouse SIRPα extracellular domain mAb P84 was purchased
from BD Biosciences. CHO cells producing the fusion protein of
human CD47 extracellular domain and alkaline phosphatase
(CD47-AP) had been previously generated and the resulting
CD47-AP in the medium was purified, as described previously
[7,26]. Recombinant human monocyte chemotactic protein 1
(MCP-1), methyl-β-cyclodextrin (MβCD), triparanol, cholesterol
oxidase (CO), filipin were purchased from Sigma. Chemicals,
including 3,3´-dithiobis(sulfosuccinimidyl)propionate (DTSSP),
Sulfo-NHS-Biotin, and NHS-Biotin, were from Pierce.
Immunofluorescence labeling of cells
To assess SIRPα expression on the cell surface, monocytes
and macrophages were blocked with 2% BSA for 30 min
followed by incubation with anti-SIPRα-ex for human cells and
CHO, and mAb P84 for murine cells (2 µg/ml each) for 60 min
(25°C). Cells were washed, incubated with Alexa Fluor-
conjugated secondary antibodies and then analyzed by
fluorescence microscopy and/or FACS. To distinguish
monocytes in PBMC, the cells were co-stained with the anti-
CD14 (2 µg/ml) antibody (BD Biosciences). Lymphocytes were
detected by staining with the anti-Lck (Cell Signaling) and anti-
CD45R/B220 (BioLegend) antibodies, while mouse
macrophages were identified by co-staining with the anti-F4/80
antibody (BioLegend). Control staining was performed using
isotype-matched IgG or the corresponding secondary
antibodies alone. To identify lipid rafts, cells were co-stained
with the Alexa Fluor 488-conjugated cholera toxin B subunit
(CT-B) (Life Technologies). For perturbation of the lipid rafts,
PMA-induced THP-1 cells were treated with MβCD (10 mg/ml),
filipin (0.5 µg/ml), triparanol (5 µM) or cholesterol oxidase (CO,
Dynamic Regulation of SIRPα-CD47 Interaction
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e77615
1 unit/ml) for 1 h (former two agents) or 12 h (latter two agents)
under cell culture conditions prior to cell staining. For kinase
inhibition, THP-1 cells were treated with genistein (100 µg/ml)
(Sigma), PP1 (35 µM) (BioMol), the genistein analog daidzein
(non-inhibitory, 100 µg/ml) (BioMol), a mixture of MAP kinase
inhibitors SB203580 (p38 inhibitor) (BioMol) and PD98059
(p42/44 MEK) (Calbiochem) (20 µM each), the
phosphatidylinositol 3 (PI3) kinase inhibitor LY294002 (25 µM)
(Calbiochem), the Bruton's tyrosine kinase (Btk) inhibitor LFM-
A13 (100 µM) (Calbiochem), the Janus protein tyrosine kinase
(JAK) inhibitor (JAK inhibitor I) (100 nM) (Calbiochem), which
inhibits JAK1, JAK2, and JAK3, on day 2 and again on day 3
during PMA-induced macrophage differentiation. Cells were
collected on day 4 for immunofluorescence staining.
SDS-PAGE, immunoblot, dot blot, biotinylation, protein
cross-linking and equilibrium centrifugation
Cells were lysed in a cold lysis buffer containing 50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, protease inhibitor
cocktail (1:50 dilution, Sigma) and 3 mM PMSF. After
centrifugation, the supernatant lysates were collected. For
western blot (WB) analysis, lysates were applied to SDS-PAGE
and transferred to nitrocellulose. After blocking with 5% non-fat
milk, the membrane was incubated with the appropriate
primary antibodies followed by detection using the
corresponding horseradish peroxidase (HRP)-conjugated
secondary antibodies and ECL. For dot blot experiments, cell
lysates were adsorbed to the nitrocellulose membrane by
vacuum, blocked and detected with primary and secondary
antibodies. For protein biotinylation, PMN and PBMC were
treated with 2 mM NHS-biotin (cell permeable) or Sulfo-NHS-
biotin (non-permeable) for 60 min (25°C), followed by washing
and quenching with 100 mM glycine. Following cell lysis,
SIRPα in PMN and PBMC was immunoprecipitated using the
anti-SIRPα.ex-conjugated Sepharose and total and biotinylated
SIRPα was detected using anti-SIRPα.ct and HRP-conjugated
streptavidin, respectively. To cross-link cell surface proteins,
monocytes and macrophages were treated with DTSSP for 30
min (25°C). After quenching, cells were lysed and SIRPα was
analyzed by SDS-PAGE and WB under non-reducing and
reducing conditions (+DTT); the reducing condition reverses
DTSSP crosslinking. To detect the SIRPα complexes by
equilibrium centrifugation, cell lysates with or without DTSSP
crosslinking were supplemented with 5% sucrose and laid on
top of sucrose density gradients (5-35% for human monocytes
and 15-45% for mouse macrophages) prepared in 1.2 ml thick-
walled ultracentrifuge tubes (Beckman Coulter).
Ultracentrifugation was carried out using a TLS-55 rotor in an
Optima TL Ultracentrifuge (Beckman Coulter) at 165,000 g for
14 h (4°C). Ten fractions (100 µl each) were collected and
SIRPα was analyzed by SDS-PAGE and WB. A biotinylated
protein marker ranging from 40-250 kD (BioRad) was
ultracentrifugated along with the cell lysates to serve as the
MW reference.
Cell adhesion assay to test SIRPα-mediated cell
interaction
Purified CD47-AP (10 µg/ml in HBSS) was immobilized by
incubation in 96-well microtiter plates for 2 h (25°C). After
blocking with 1% BSA, the cell suspension (1 x 106) in 50 µl
blocking buffer was added into CD47-AP-coated wells, in the
presence or absence of antibodies or fusion proteins (10 µg/
ml), followed by stationary incubation for 30 min (25°C). The
wells were then gently washed three times and cells that
adhered were determined by microscopy. To calculate cell
adhesion percentile, cells were labeled with the fluorescent dye
BCECF (Molecular Probes) prior to incubation with CD47-AP.
The fluorescence intensities of the cells before and after
washing were recorded using a fluorescence plate reader at
excitation and emission wavelengths of 485 and 535 nm,
respectively.
Monocyte transendothelial migration
To establish endothelial monolayers, HMEC-1 cells were
cultured on polycarbonate transwells (0.33 cm2, 5 µm pore
size, Corning) until confluence. To induce monocyte
transmigration, freshly isolated human PBMC (5 x 106,
containing ~1 x 106 monocytes) were added to the upper
chamber of the transwells in 150 µl RPMI 1640 followed by
addition of MCP-1 (50 ng/ml) in 0.5 ml the same medium into
the lower chamber (supplemental data). After incubation for 2 h
(37°C), monocytes that transmigrated into the lower chamber
were collected for further analysis.
SIRPα purification and examination of binding to CD47
After lysis of various cells, SIRPα in detergent soluble
supernatants was incubated with anti-SIRPα.ex-conjugated
Sepharose for 3 h (4°C). The Sepharose beads were washed
with Tris buffer, pH 7.5, containing 1% n-octyl-β-D-
glucopyrannoside (OG). Elution of SIRPα was performed using
100 mM sodium acetate, pH 4.0, containing 1% OG, followed
by immediate neutralization with 1.0 M Tris buffer, pH 8.0.
Affinity purified SIRPα was confirmed by WB using anti-
SIRPα.ex and anti-SIRPα.ct antibodies. To examine SIRPα
binding to CD47, purified SIRPα was diluted in HBSS (1:10)
and immobilized in 96-well microtiter plates (2 h, 4°C). After
blocking, the wells were incubated with CD47-AP (1 µg/ml) for
30 min (25°C) in the presence or absence of inhibitory
antibodies. After washing, CD47 binding was detected using
the AP substrate p-nitrophenylphosphate (pNPP, Sigma). In
some experiments, dot blots were conducted by absorption of
purified SIRPα onto nitrocellulose. After blocking, the
membrane was incubated with CD47-AP (1 µg/ml) followed by
the analysis of AP activity using NBT (nitro-blue tetrazolium
chloride) and BCIP (5-bromo-4-chloro-3'-indolyphosphate p-
toluidine salt) (Promega). The densities of the dots were
quantified using the NIH densitometry software Image J.
Dynamic Regulation of SIRPα-CD47 Interaction
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Results
Peripheral monocytes express ample SIRPα on the cell
surface but do not effectively interact with CD47
We examined SIRPα expression in human peripheral
granulocytes (PMN) and peripheral mononuclear cells (PBMC).
As shown in Figure 1A, immunoblotting (WB) using polyclonal
antibodies against the SIRPα extracellular domain (anti-
SIRPα.ex) or the cytoplasmic tail (anti-SIRPα.ct) detected the
abundant expression of SIRPα (~65-85kD) in human PMN and
PBMC. Cell surface immunofluorescence labeling showed that
in PBMC, SIRPα is selectively expressed on CD14+ monocytes
but not on lymphocyte-specific protein tyrosine kinase (Lck)+ T
cells or B220+ B lymphocytes (Figure 1B), confirming previous
results [25]. Protein biotinylation assays to compare SIRPα
distribution in monocytes and PMN showed that SIRPα in PMN
was labeled with biotin only following membrane
permeabilization, as shown in Figure 1C. This was in
agreement with our previous finding indicating that the majority
of SIRPα is stored in intracellular pools in PMN prior to
chemoattractant stimulation [31]. However, when labeling
PBMC, we observed strong biotinylated SIRPα under both
permeable and impermeable conditions, suggesting that SIRPα
was distributed on the monocyte surface. FACS analysis
confirmed that the majority of SIRPα is directly distributed on
the monocyte cell surface, as membrane permeabilization did
not show additional labeling (Figure 1D). Similar results were
obtained when detecting SIRPα expression in monocyte-like,
THP-1 and U-937 cells, in which the majority of SIRPα was
found on the cell surface instead of being located in
intracellular pools (Figure S1).
While SIRPα is significantly expressed on the cell surface,
we found that peripheral monocytes, as well as cultured THP-1
and U-937, could not effectively interact with extracellular
CD47. The cell adhesion assay, depicted in Figure 2A, was
used to test SIRPα-mediated cellular adhesion interactions with
recombinant CD47 containing the SIRPα-binding domain
(CD47-AP) [7]. As shown in Figure 2B, none of the human
PBMC (~30% monocytes), CD14-enriched monocytes (>90%
purity), cultured THP-1 or U-937 cells adhered to immobilized
CD47-AP. In contrast, the control CHO cells with SIRPα over-
expression (CHO-SIRPα), but not the mock-transfected cells,
displayed direct CD47-AP adhesion (Figure 2C). Addition of
either the anti-SIRPα mAb SE5A5 or the anti-CD47 mAb
B6H12.2 completely eliminated CHO-SIRPα adhesion (Figure
2D), confirming the presence of the SIRPα and CD47-mediated
cell surface interaction. FACS analyses revealed that CHO-
SIRPα expressed significantly higher amounts of SIRPα on the
cell surface than monocytes (Figure 2E), suggesting that the
density of SIRPα may play an important role in SIRPα-
mediated cell surface binding interactions.
Activated monocytes and macrophages mediate high
avidity binding to CD47 via SIRPα
Previous reports have shown that monocyte transmigration
in response to inflammatory challenge involves the interaction
of SIRPα on the monocyte surface with CD47 expressed on
tissue cells [6], suggesting that the activation of monocytes
might be required for SIRPα to interact with CD47. To test this,
we treated freshly isolated PBMC with MCP-1, and also
induced monocytes to transmigrate across HMEC-1
monolayers towards MCP-1 (depicted in Figure S2). As shown
in Figure 3, direct treatment with MCP-1, a method which is
known to partially activate monocytes, only slightly increased
monocyte adhesion to CD47-AP. In contrast, monocytes that
were induced to transmigrate across HMEC-1 monolayers
exhibited remarkable binding to CD47-AP. Addition of inhibitory
anti-SIRPα mAbs (SE5A5 and SE7C2) or a soluble SIRPα
extracellular domain (SIRPα.ex Fc), which competitively binds
to CD47, abrogated the adhesion of transmigrated monocytes
to CD47-AP, confirming the SIRPα-mediated cell surface
interaction (Figure 3).
Similarly, we tested if the activation/differentiation of THP-1
cells would alter SIRPα-mediated cell binding. In these
experiments, THP-1 cells were treated with PMA for 3-4 days
to induce macrophage phenotypic differentiation. In contrast to
non-induced THP-1 cells that displayed no adhesion, PMA-
induced THP-1 macrophages demonstrated readily binding to
CD47 (Figure 3). Inhibition of SIRPα-CD47 extracellular
interaction with mAbs and SIRPα.ex Fc completely eliminated
the THP-1 macrophage adhesion (Figure 3). Further, FACS
analyses of THP-1 macrophages, as well as transmigrated
monocytes, showed similar labeling intensities on these cells
as on non-differentiated THP-1 or naïve monocytes (Figure
3C), suggesting that the enhanced adhesion to CD47 was not
due to increases in SIRPα expression.
To examine if the failure of binding to CD47 by naïve
monocytes and non-differentiated THP-1 is due to the SIRPα
incompetent binding (contrary to the competent binding on
transmigrated monocytes and THP-1 macrophages), we affinity
purified SIRPα from different cells and compared their direct
binding. As shown in Figure 4A, SIRPα in the different cell
lysates was affinity absorbed to anti-SIRPα.ex-conjugated
Sepharose and, after washing, was eluted at pH 4.0 in a buffer
containing 1% OG. Purified SIRPα was then immobilized onto
microtiter plates (Figure 4B) or nitrocellulose (Figure 4C),
followed by testing for direct CD47 binding. As shown, all
purified SIRPα, including those from naïve monocytes and non-
differentiated THP-1, displayed effective binding to CD47,
implying that the differences of cellular interactions are unlikely
caused by alterations in the SIRPα structure or the
modification.
SIRPα clusters on activated monocytes and
macrophages
Interestingly, when conducting the cell surface labeling, we
observed that the distribution of SIRPα on naïve monocytes is
different from that on transmigrated monocytes or
macrophages. As shown in Figure 5A, SIRPα presents as a
diffuse distribution pattern on freshly isolated human
monocytes, but a highly punctate staining pattern on
transmigrated monocytes and THP-1 macrophages. This
suggests that SIRPα is clustered at the plasma membrane.
Similar diffuse and punctate staining patterns of SIRPα were
also observed when labeling murine peripheral monocytes and
macrophages, respectively (Figure 5A). Both peritoneal
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macrophages (PEM) and bone marrow derived macrophages
(BMDM) displayed highly punctate SIRPα staining on the cell
surface. Given that CD47 is also expressed in monocytes and
macrophages, we assessed if SIRPα clustering involves
interactions with CD47 in the same membrane (cis-interaction).
However, double staining of THP-1 macrophages and BMDM
showed that CD47 displayed a mixture of diffuse and punctate
pattern that did not largely overlap with the staining of SIRPα
(Figure 5B).
To confirm SIRPα clustering on activated/differentiated
leukocytes, we performed chemical crosslinking using a cell-
impermeable crosslinker DTSSP. As shown in Figure 5C,
DTSSP was unable to crosslink SIRPα on naïve monocytes,
which remained to be resolved as the monomer by SDS-PAGE
(70-80 kD and 110-120 kD for human and murine SIRPα,
respectively). In contrast, DTSSP dramatically crosslinked
SIRPα on transmigrated monocytes and macrophages,
resulting in SIRPα shifting to a much larger size that was barely
resolved by 8-10% polyacrylamide gel electrophoresis.
Figure 1.  Expression of SIRPα on monocytes.  Detection of SIRPα by WB in freshly isolated human PBMC and PMN using anti-
SIRPα.ex (SIRPα.ex) and anti-SIRPα.ct (SIRPα.ct) antibodies. B) Immunofluorescence staining of PBMC. Cell surface SIRPα was
labeled with anti-SIRPα.ex under non-permeable conditions. Monocytes (arrow heads) were defined by anti-human CD14 antibody,
and T and B lymphocytes were defined with anti-Lck and anti-B220 antibodies, respectively. C) Determination of the distribution of
SIRPα in PMN and monocytes by cell biotinylation. Cells were biotinylated with either NHS-biotin (cell permeable) or sulfo-NHS-
biotin (non-cell permeable), followed by the IP of SIRPα from the lysates. Biotinylated and total SIRPα were blotted by streptavidin-
HRP and anti-SIRPα.ct, respectively. The same amount of protein was used for IP as confirmed by the actin blots. D) FACS
analysis to determine SIRPα in monocytes labeled under cell permeable and non-permeable conditions.
doi: 10.1371/journal.pone.0077615.g001
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Reversal of the cross-linking by DTT instantly resolved SIRPα
to its monomeric size (Figure 5C). This remarkable change of
SIRPα by crosslinking was consistent with the cell labeling
observation, suggesting that SIRPα is clustered to large
complexes on activated monocytes and macrophages.
However, these SIRPα complexes remained in the detergent-
soluble lysates, as dot blots without gel electrophoresis
detected the protein (Figure 5C). We also investigated if
SHP-1/2, the intracellular signaling molecule downstream of
SIRPα, would be affected by DTSSP crosslinking. As shown, in
naïve monocytes and unstimulated THP-1 cells, SHP-1
resolves as a distinctive protein of ~65kD, despite DTSSP
treatment. Interestingly, SHP-1 could not be detected in
transmigrated monocytes and macrophages after DTSSP
cross-linking, suggesting that SHP-1 also formed protein
complexes. As SHP-1 stays intracellularly and DTSSP is
membrane impermeable, the complexes of SHP-1 observed by
DTSSP treatment are thus likely formed through protein
interactions with certain transmembrane partners such as
SIRPα. To determine the size of SIRPα complexes, lysates
prepared from DTSSP-treated cells were applied to sucrose
density gradients followed by equilibrium ultracentrifugation. As
shown in Figure 5D, the sedimentation of crosslinking-
stabilized SIRPα complexes from transmigrated monocytes
and macrophages was significantly faster than the monomeric
SIRPα from PBMC and the non-crosslinked macrophages.
Judging by the reference protein markers, the sizes of SIRPα
complexes formed in human monocytes and murine
macrophages were both ≥250kD (Figure S3).
Figure 2.  SIRPα in naïve monocytes do not mediate cell adhesion to immobilized CD47.  A) Schematic depiction of the cell
adhesion assay. B) Adhesion of different cells to immobilized CD47-AP. Cell suspensions were incubated with CD47-AP or BSA
(ctl.) for 30 min (25°C), followed by washing. C) Percentage of cell adhesion to CD47-AP versus BSA. D) Control adhesion
performed using CHO cells with or without SIRPα transfection (CHO-mock and CHO-SIRPα, respectively), and in the presence or
absence of inhibitory anti-SIRPα (SE5A5) and anti-CD47 (B6H12.2) mAbs (20 μg/ml for each). The data are expressed as the
means ± SE and represent three independent experiments with triplicate wells per cell type. ***, P <0.001. E) FACS analyses of
SIRPα on the cell surfaces of peripheral monocytes and CHO-SIRPα cells.
doi: 10.1371/journal.pone.0077615.g002
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SIRPα clustering involves cholesterol-rich membrane
rafts and actin filaments
As the cholesterol-rich lipid rafts in the plasma membrane
play a critical role in the assembly of important cell surface
structures, we investigated the role of lipid rafts in clustering
SIRPα on activated monocytes and macrophages. As shown in
Figure 6A, brief (30 min) treatments of THP-1 macrophages
with MβCD, a widely used cholesterol-depleting/lipid raft
perturbation reagent, disassembled the SIRPα clusters on the
cell surface. Likewise, inhibition of cholesterol biosynthesis with
triparanol or modifying cholesterol with cholesterol oxidase
(CO) also dispersed the SIRPα complexes. Treatment with
filipin, which binds cholesterol but does not necessarily perturb
the lipid rafts [32,33], however, did not disassociate SIRPα
clusters. The concomitant labeling of cell surface ganglioside
GM1, a characteristic lipid raft marker, with cholera toxin B
subunit (CT-B) revealed that the majority of SIRPα co-localized
within the lipid rafts (~55-65%, calculated by the ZEISS
microscope software ZEN) (Figure 6B). Furthermore, the loss
of SIRPα clusters correlated with a reduction in the strength of
THP-1 macrophage binding to CD47. As shown in Figure 6C,
treating PMA-differentiated THP-1 with MβCD, triparanol and
CO, but not filipin, resulted in the attenuation of SIRPα-
mediated cell binding to CD47-AP. As the actin cytoskeleton
Figure 3.  SIRPα in activated monocytes and macrophages mediate high avidity cell adhesion to immobilized CD47.  To
obtain activated monocytes, freshly isolated PMBC were treated with 50 ng/ml MCP-1 (37°C, 1 h) and were also induced to
transmigrate across HMEC-1 endothelial monolayers by MCP-1. To obtain macrophages, THP-1 cells were treated with PMA (50
nM) for 3-4 days. A) Cell adhesion assays. SE5A5 and SE7C2 are both inhibitory anti-SIRPα mAbs. B) Percentage of cell adhesion
to CD47-AP versus BSA. ***, P <0.001. C) FACS analysis of SIRPα on the surface of naïve (PBMC) and activated monocytes,
unstimulated and stimulated THP-1 using anti-SIRPα.ex antibody.
doi: 10.1371/journal.pone.0077615.g003
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has been well recognized as a dynamic regulator of lipid raft
stability, we also treated cells with cytochalasin D to disrupt
actin filaments. As shown, brief treatment with cytochalasin D
(30 min) largely diminished SIRPα clusters on THP-1
macrophages. Altogether, these results suggest that
cholesterol-rich lipid rafts are critically involved in clustering
and stabilization of SIRPα complexes during monocyte
activation and/or differentiation into macrophages.
Involvement of Src family tyrosine kinase in the
formation of SIRPα clusters
To investigate the potential mechanisms that control the
SIRPα complex formation, inhibitors targeting different
signaling pathways were tested during PMA-induced THP-1
differentiation into macrophages. As shown in Figure 7A,
inhibiting the Src family tyrosine kinases with PP1 and
genistein significantly blocked SIRPα clustering on the cell
surface. On the contrary, treating THP-1 with daidzein, a
genistein analog that lacks tyrosine kinase inhibition, had no
effect. Inhibition of other signaling pathways including PI3
kinase (LY294002), MAP kinases such as p38 MAP (SB
203580) and MAP kinase kinase (PD 98059), Janus kinases
(JAK1-3) and Bruton's tyrosine kinase (Btk) (LFM-A13) did not
affect the formation of SIRPα complexes. Consistent with the
pattern of SIRPα distribution on the cell surface, cell adhesion
assays demonstrated that the treatment with genistein and
PP1, but not the other inhibitors, eliminated THP-1
macrophage binding to CD47 (Figure 7B).
Discussion
This study was initiated following the observation that
peripheral monocytes express abundant SIRPα on the cell
Figure 4.  Purified SIRPα binding to CD47.  SIRPα, affinity purified from naïve and activated monocytes and unstimulated and
stimulated THP-1, was tested for direct binding to CD47-AP. A) Affinity purification of SIRPα. SIRPα in different cell lysates was
absorbed by anti-SIRPα.ex-conjugated Sepharose and eluted at pH 4.0 in the presence of 1% OG. B) Binding of purified SIRPα
from various sources to CD47-AP. Purified SIRPα was immobilized in 96-well plates following a 1:10 dilution of OG. Binding to
CD47 was tested by incubation with CD47-AP (2 μg/ml, 30 min), followed by washing and detection of AP activity. The figure inset
shows similar amounts of immobilized SIRPα in the wells as detected by WB (anti-SIRPα.ct). C) Binding of SIRPα purified from
PBMC to CD47-AP in the presence of inhibitory anti-SIRPα (SE5A5) and anti-CD47 (B6H12.2) mAbs, or SIRPα.ex Fc. Purified
SIRPα samples were absorbed onto 96-well plates (lower panel) or nitrocellulose membrane (upper panel). Following blocking with
BSA and incubation with CD47-AP, the binding was assessed by AP activity.
doi: 10.1371/journal.pone.0077615.g004
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surface but do not mediate cell binding interactions with the
extracellular ligand CD47. Unlike PMN, which store the majority
of SIRPα in intracellular granules to be released only after
inflammatory stimulation [31], naïve monocytes lack
intracellular SIRPα pools but display a majority of SIRPα on the
cell surface. Despite ample SIRPα on the surface, peripheral
monocytes maintain low adhesive interactions with CD47 or
CD47-expressing cells, e.g., RBCs. In fact, no monocyte
aggregation with RBCs under physiological conditions has ever
been observed in the peripheral blood stream, even in the
microvasculature in which the blood flow is slow. In this study,
more definitive evidence confirming the inefficient binding of
monocytes to CD47 was obtained by testing peripheral
monocytes, or monocytic THP-1 and U937, for direct adhesion/
binding to purified recombinant CD47 in vitro.
While naïve monocytes must avoid adhesive interactions to
maintain peripheral blood homeostasis under resting
conditions, activated monocytes and monocyte-differentiated
macrophages require constant interaction with the surrounding
cells when migrating through endothelial monolayers and
tissues during inflammation or for immune surveillance. Studies
have shown that SIRPα and CD47-mediated cell surface
Figure 5.  SIRPα on activated monocytes and macrophages forms clusters/complexes.  A) Assessing SIRPα on naïve PBMC,
transmigrated monocytes, PMA-induced THP-1 and murine macrophages by immunofluorescence staining using anti-SIRPα.ex and
mAb P84, an antibody specific for the murine SIRPα extracellular domain. B) Staining of SIRPα and CD47 on PMA-stimulated
THP-1 using anti-SIRPα.ex and mAb B6H12.2. C) DTSSP crosslinking to assess protein complexes consisting SIRPα. Different
cells were treated with DTSSP (25°C, 30 min) prior to lysis in detergent-containing buffer. Lysate samples were analyzed by SDS-
PAGE and WB under non-reducing or reducing (+DTT) conditions. The latter reverses the DTSSP crosslinking. Note: murine SIRPα
appears to be 110-120 kD, larger than the human counterpart. Dot blot detection of SIRPα was performed by directly absorbing cell
lysates onto nitrocellulose, prior to antibody blotting. D) Equilibrium centrifugation analysis of SIRPα complexes. After DTSSP
crosslinking, cell lysates were applied to ultracentrifugation in sucrose density gradients. Following fractionation, SIRPα localization
was analyzed by WB and compared to the sedimentation of a reference protein marker.
doi: 10.1371/journal.pone.0077615.g005
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interactions play a critical role in monocyte chemotactic
transmigration and macrophage recognition of phagocytic
targets. Inhibition of the SIRPα-CD47 interaction delays
monocyte transmigration [6] and also perturbs macrophages to
elicit intracellular signaling, which normally restrains
phagocytosis of the surrounding cells [2,17-22,34].
Consistently, our cell adhesion assays showed that monocytes
that had been activated and had transmigrated through the
endothelial monolayers or that had differentiated into
macrophages displayed significant direct binding to CD47. The
striking difference between the activated monocytes/
macrophages and the naïve monocytes in CD47 binding, and
the lack of information on the mechanism(s) by which cell
binding is so dynamically controlled, motivated the studies
presented here.
Our investigations led to the following conclusions: first, the
levels of SIRPα in the plasma membrane did not differ
considerably between naïve and activated monocytes or un-
induced and induced THP-1 macrophages. Second, by
isolating individual SIRPα proteins from both naïve and
activated monocytes and macrophages, we excluded the
possibility that a conformational change or modifications in the
SIRPα extracellular domain as the likely mechanism conferring
CD47 binding. Third, there is a difference in the distribution of
SIRPα on cell surfaces between naïve and activated
monocytes or macrophages. When activated by cytokines and
during transmigration, monocytes experience a redistribution of
SIRPα, from being dispersed in the plasma membrane to
cluster into multi-stranded protein complexes. This ‘clustered’
SIRPα distribution confers high avidity binding to CD47 at the
cell surface, enabling monocytes transmigrating across
endothelial monolayers. Similarly in macrophages, the cell
surface bundling of SIRPα allows high avidity interactions with
CD47 displayed on the encountered cells, leading to strong
ITIM-mediated signaling and inhibition of phagocytosis (Figure
7C). In addition, our studies also found that SIRPα complexes
are stabilized by cholesterol-rich ‘lipid rafts’ in the plasma
membrane. Disruption of the lipid rafts by cholesterol-depletion
or raft perturbation caused disassembly of SIRPα clusters on
the cell surface, concomitant with reduced cell binding to
CD47. Intriguingly, instead of resistance to non-ionic detergent,
we found that the SIRPα complex-associated ‘lipid rafts’ are
sensitive to Triton X-100 solubility and only partially co-localize
with flotillin, a lipid raft marker [35], as analyzed by WB (Figure
S3). Perhaps, the increased sensitivity to detergent indicate
that these lipid rafts consisting of SIRPα complexes are rather
“soft” and may contain relatively low levels of saturated lipids,
thus providing a high degree of lipid and protein binding
dynamics. In fact, similar ‘soft’ rafts have been reported to
associate with other important receptors on the cell surface.
These include the T cell antigen receptor (TCR) [36],
immunoglobulin E (IgE) receptor [37], some Fc receptors [38],
and ion channels [39], etc. The mechanisms involved in
Figure 6.  Clustering of SIRPα on cell surfaces requires cholesterol-rich lipid rafts.  PMA-stimulated THP-1 cells were treated
with lipid raft/cholesterol perturbation/modification agents, including MβCD (10 mg/ml), triparanol (5 µM), cholesterol oxidase (CO)
(1 unit/ml) and filipin (0.5 µg/ml), prior to A) assessment of SIRPα on the cell surface by immunofluorescence staining, B) analysis of
SIRPα localization in lipid rafts by co-staining for raft marker GM1 by cholera toxin B subunit (CT-B), C) assay of SIRPα-mediated
cell adhesion to immobilized CD47-AP. **, P <0.01. ***, P <0.001. The effect of the actin filament disruption agent cytochalasin D on
lipid rafts and SIRPα distribution was also tested (shown in C).
doi: 10.1371/journal.pone.0077615.g006
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formation of this particular raft, or other types of membrane
microdomains, remain unresolved.
We further explored if the formation of SIRPα complexes on
activated monocytes and macrophages is controlled by specific
signal transduction mechanisms. Our studies showed that
inhibition of the Src family tyrosine kinase by PP1 and genistein
prevented the clustering of SIRPα during THP-1 differentiation
into macrophages, suggesting that Src kinase-mediated
tyrosine phosphorylation plays a key role in bundling SIRPα
into lipid rafts. One of the likely targets for Src kinase appears
to be SIRPα itself, as its essential cytoplasmic ITIMs contain
four tyrosine residues. Consistent with this postulation, the
study by Johansen et al. [40] observed that in adhesive
macrophages, SIRPα exists as a tyrosine phosphorylated
protein, and the status of SIRPα modification is independent of
extracellular CD47 ligation. Studies in other cell types,
including kidney podocytes and melanoma cells, suggested
that SIRPα maintains tyrosine phosphorylation in the
cytoplasmic domain and association with SHP-(1/2); cell
surface CD47 ligation, on the other hand, triggers SIRPα
dephosphorylation and releases SHP proteins [4,41]. Perhaps
the formation of SIRPα complexes in the lipid rafts of activated
Figure 7.  Role of the Src family tyrosine kinase in SIRPα clustering.  THP-1 cells were induced to differentiate into
macrophages by treating with PMA for 5 days. From day 3, various pharmacological inhibitors were added into the cell culture,
including the Src tyrosine kinase inhibitors genistein (100 µg/ml) and PP1 (35 µM), the genistein analog daidzein (non-inhibitory,
100 µg/ml), a mixture of MAP kinase inhibitors (MAP combo) SB203580 and PD98059 (20 µM each), the PI3 kinase inhibitor
LY294002 (25 µM), the Btk inhibitor LFM-A13 (100 µM), the JAK inhibitor (JAK inhibitor I, 100 nM). A) Immunofluorescence staining
of SIRPα on the THP-1 surface by anti-SIRPα.ex. B) Assay of SIRPα-mediated cell adhesion to immobilized CD47-AP. ***, P
<0.001. C) A model of SIRPα distribution and complex formation on monocytes and macrophages.
doi: 10.1371/journal.pone.0077615.g007
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monocytes and macrophages, which is a result of cytokine
stimulation, requires SIRPα cytoplasmic ITIM phosphorylation
and subsequent association with SHP (Figure 7C). Indeed, the
cell surface crosslinking of activated monocytes and
macrophages impeded not only SIRPα but also SHP-1 from its
monomeric MW, suggesting that SHP-1 is also formed protein
complexes. As the crosslinker is membrane-impermeable, the
formation of SHP-1 complexes must be a result of
intermolecular interactions with transmembrane proteins such
as SIRPα (Figure 7C). It is possible that well-assembled, multi-
stranded SIRPα-SHP complexes in the lipid rafts facilitate high
avidity and stable interactions with CD47 in activated
monocytes or macrophages migrating in tissues; these
structures also allow prompt and robust intracellular signals
that prevent monocytes/macrophages from attacking
encountered the self cells.
Supporting Information
Figure S1.  Immunofluorescence staining of SIRPα in
THP-1 and U937. SIRPα in THP-1 and U937 cells were
labeled by anti-SIRPα.ex antibody under non-membrane
permeable and membrane-permeable conditions. Labeling with
isotype-matched IgGwas performed as controls. Labeled cells
were analyzed by FACS.
(PDF)
Figure S2.  Schematic depiction of monocyte
transmigration. HMEC-1 cells were cultured on the transwell
filter (with 5 μm pore size) until confluency. For monocyte
transmigration, freshly isolated PBMC were added to the upper
chamber of the setup and MCP-1 (50ng/ml ) was added into
the lower chamber. Following incubation at 37°C (2h),
monocytes that transmigrated across the endothelial
monolayer into the lower chamber were harvested and used for
cell adhesion assays and other experiments.
(PDF)
Figure S3.  SIRPα-containing complexes are sensitive to
Triton X-100 and other detergents. A) Peripheral PBMC,
transmigrated monocytes, and BM-derived macrophages
(BMDM) were lysed in cold lysis buffer containing 50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, protease
inhibitors. After centrifugation, the supernatants were
separated and labeled as soluble fractions (S). The pellets
were further lysed in lysis buffer containing 0.5% SDS and
designated as insoluble fractions (I). Soluble and insoluble
fractions were analyzed by SDS-PAGE and WB by anti-
SIRPα.ct and anti-Flotillin-1 antibodies. B) Same experiments
were performed as in A except using Brij 58 as the detergent.
(PDF)
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